Tempus AI TEM stock saw a positive improvement to its Relative Strength (RS) Rating on Thursday, rising from 66 to 78. Please ...

Tempus AI achieves strong revenue growth and beats expectations, but ongoing losses and execution risks temper enthusiasm.

Tempus AI’s TEM stock has surged nearly 13% since its second-quarter 2025 earnings release. The quarter saw strong top-line ...

Although shares have retreated from their all-time high, those who bought shares one year ago are still looking at growth in ...

In conjunction with its better-than-expected sales growth in the second quarter, Tempus AI raised its sales outlook for this ...

TEM surged 34.5% in Q2 on AI-driven deals and product momentum, but valuation and profit concerns linger ahead of earnings.

Tempus AI Inc is a technology company. It has built the Tempus Platform, which comprises both a technology platform to free healthcare data from silos and an operating system to make the resulting ...

Tempus AI offers a strong business model with AI-driven genomic data, resilient demand, and significant growth prospects. Click here to read why TEM is a Hold.

Tempus AI delivered adjusted EBITDA of -$21.8 million in the third quarter, which was a $14.4 million year-over-year improvement and also a significant improvement quarter over quarter.

Tempus Ai (NASDAQ: TEM) stock is seeing an explosive valuation surge in Tuesday's trading thanks to a pair of catalysts. The healthcare software company's share price was up 35.8% as of 3:15 p.m ...

Completing its initial public offering on June 14, Tempus AI stock closed at $40.25, and while it rose above this mark from time to time in the second half of 2024, the stock ended the year on a ...

The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Tempus Ai wasn’t one of them.